Alpha-Galactosidase لـ Bloating and Intestinal Gas
B الأدلة تدعم ذلك تجربة عشوائية واحدة على الأقل، مع نتائج متسقة في معظمها.Reduces gas symptoms from high-fiber foods containing raffinose/stachyose by 50-70%. Beano (alpha-galactosidase 300 GalU) is the most studied formulation.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dalpha\u002Dgalactosidase\u0026condition\u003Dbloating\u002Dand\u002Dgas';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
الخلاصة
Reduces gas symptoms from high-fiber foods containing raffinose/stachyose by 50-70%. Beano (alpha-galactosidase 300 GalU) is the most studied formulation.
Key Study Findings
Review
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Dose: None
مقابل: None
Outcome: None
التأثير: None
None
المجتمع المدروس: None
Randomized Controlled Trial
Double-blind
A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal …
Dose: 1200 G
مقابل: placebo
Outcome: every 30 min during 7
التأثير: None
None
المجتمع المدروس: patients with ibs after three standardized
Other
n=17
FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument.
Dose: None
مقابل: no treatment
Outcome: None
التأثير: None
None
المجتمع المدروس: fabry disease but are often nonspecific
Randomized Controlled Trial
n=31
2.0 weeks
Double-blind
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Dose: 300 GALU or 150 GALU
مقابل: Placebo (glucose)
Outcome: GI symptom severity on VAS
التأثير: None
pP0.006
المجتمع المدروس: IBS patients (Rome III, H2 producers)
Randomized Controlled Trial
n=125
4 weeks
Double-blind
Does oral α-galactosidase relieve irritable bowel symptoms?
Dose: alpha-galactosidase 600 GalU per meal
مقابل: placebo
Outcome: overall IBS symptom relief
التأثير: no significant difference vs placebo
>0.05
المجتمع المدروس: IBS patients
Case Reports
A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha …
Dose: 3.7nmol/mL/h
مقابل: None
Outcome: None
التأثير: None
None
المجتمع المدروس: patients
Key Statistics
4
الدراسات
300
المشاركون
↑
Positive
B
التقييم
Referenced Papers
International journal of …
2021
16 اقتباسات
Quality of life …
2021
14 اقتباسات
Neurogastroenterology and motility
2021
4 اقتباسات
The American journal …
2018
49 اقتباسات
Scandinavian journal of …
2016
17 اقتباسات
Clinical biochemistry
2015
18 اقتباسات
BMC gastroenterology
2013
12 اقتباسات
Digestive diseases and …
2007
45 اقتباسات
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Other
Molecular genetics and …
2005
84 اقتباسات
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
الجرعات الشائعة
- general:
- 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods
- standardbeanodose:
- 300 GalU (2-3 tablets) with first bite of problem food
الحد الأعلى: No established upper limit; adjust per meal as needed
الجرعات المدروسة في الأبحاث
| الجرعة | المدة | التأثير | ن |
|---|---|---|---|
| None | -- | Mixed | -- |
| 1200 G | -- | Neutral | -- |
| None | -- | Positive | 17 |
| 300 GALU or 150 GALU | 2.0 weeks | Positive | 31 |
| alpha-galactosidase 600 GalU per meal | 4 weeks | Neutral | 125 |
| 3.7nmol/mL/h | -- | Mixed | -- |
| None | 2 weeks | Positive | -- |
| 300 or 1200 GalU | -- | Positive | 8 |
أفضل وقت للتناول: With the first bite of gas-producing food
Safety & Side Effects
الآثار الجانبية المُبلّغ عنها
- ⚠ Generally very well-tolerated
- ⚠ Rare allergic reactions to mold-derived enzyme (Aspergillus source)
- ⚠ May cause mild GI discomfort in rare cases
التفاعلات المعروفة
- ● Acarbose (alpha-galactosidase may counteract the blood sugar-lowering mechanism of acarbose; contraindicated for concurrent use)
- ● Miglitol (similar mechanism conflict as acarbose)
الحد الأقصى المسموح به: No established upper limit; adjust per meal as needed
استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.
Frequently Asked Questions
Does Alpha-Galactosidase help with Bloating and Intestinal Gas?
Based on 4 studies with 300 participants, there is moderate evidence from clinical studies that Alpha-Galactosidase may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).
How much Alpha-Galactosidase should I take for Bloating and Intestinal Gas?
Studies have used various dosages. A commonly studied range is 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Alpha-Galactosidase?
Reported side effects may include Generally very well-tolerated, Rare allergic reactions to mold-derived enzyme (Aspergillus source), May cause mild GI discomfort in rare cases. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Alpha-Galactosidase and Bloating and Intestinal Gas?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
مكونات أخرى لـ Bloating and Intestinal Gas
Alpha-Galactosidase لحالات أخرى
References
- [1] Fabio Caputo et al.. Int J Environ Res Public Health. 2021. Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review. doi:10.3390/ijerph18063320 PubMed
- [2] Alan L Shields et al.. Qual Life Res. 2021. FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument. doi:10.1007/s11136-021-02847-9 PubMed
- [3] Lena Böhn et al.. Neurogastroenterol Motil. 2021. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome … doi:10.1111/nmo.14094 PubMed
- [4] C J Tuck et al.. Am J Gastroenterol. 2018. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. doi:10.1038/ajg.2017.245 PubMed
- [5] Markku Hillilä et al.. Scand J Gastroenterol. 2016. Does oral α-galactosidase relieve irritable bowel symptoms? doi:10.3109/00365521.2015.1063156 PubMed
- [6] Antonino Tuttolomondo et al.. Clin Biochem. 2015. A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene. doi:10.1016/j.clinbiochem.2014.09.018 PubMed
- [7] Giovanni Di Nardo et al.. BMC Gastroenterol. 2013. Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. doi:10.1186/1471-230X-13-142 PubMed
- [8] Michele Di Stefano et al.. Dig Dis Sci. 2007. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. doi:10.1007/s10620-006-9296-9 PubMed
- [9] Maryam Banikazemi et al.. Mol Genet Metab. 2005. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. doi:10.1016/j.ymgme.2005.04.009 PubMed
- [10] T G Ganiats et al.. J Fam Pract. 1994. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. PubMed
إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.